Roger Burkinshaw

Adjuvant zoledronic acid in patients with early breast cancer: final efficacy analysis of the AZURE (BIG 01/04) randomised open-label phase 3 trial

Robert E. Coleman, David Cameron, David Dodwell et al. · The Lancet Oncology · 2014 · 290 citations

Breast Oncology, Early Breast Cancer, Medicine +9

Safety of zoledronic acid and incidence of osteonecrosis of the jaw (ONJ) during adjuvant therapy in a randomised phase III trial (AZURE: BIG 01–04) for women with stage II/III breast cancer

Robert E. Coleman, Emma R. Woodward, Janet E. Brown et al. · Breast Cancer Research and Treatment · 2011 · 118 citations · Full text

Bone Disease, Zoledronic Acid, Breast Oncology +10

Abstract S4-5: Adjuvant Treatment with Zoledronic Acid in Stage II/III Breast Cancer. The AZURE Trial (BIG 01/04)

RE Coleman, HC Thorpe, David Cameron et al. · Cancer Research · 2010 · 59 citations

Breast Oncology, Cancer Management, Adjuvant Chemotherapy +17

Primary and Booster Mucosal Immune Responses to Meningococcal Group A and C Conjugate and Polysaccharide Vaccines Administered to University Students in the United Kingdom

Qibo Zhang, Raman Lakshman, Roger Burkinshaw et al. · Infection and Immunity · 2001 · 49 citations · Full text

Associations Between Serum Bone Biomarkers in Early Breast Cancer and Development of Bone Metastasis: Results From the AZURE (BIG01/04) Trial

Janet E. Brown, Emma Rathbone, Samantha Hinsley et al. · JNCI Journal of the National Cancer Institute · 2017 · 43 citations · Full text